Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells (Q39085692)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 October 2013

Language	Label	Description	Also known as
English	Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells	scientific article published on 6 October 2013

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells (English)

1 reference

Europe PubMed Central

8 September 2017

1 reference

based on heuristic

inferred from title

multiple drug resistance

1 reference

based on heuristic

inferred from title

author name string

Chen Qu

1

1 reference

Europe PubMed Central

8 September 2017

Weijia Zhang

2

1 reference

Europe PubMed Central

8 September 2017

Guopei Zheng

3

1 reference

Europe PubMed Central

8 September 2017

Zijuan Zhang

4

1 reference

Europe PubMed Central

8 September 2017

Jiang Yin

5

1 reference

Europe PubMed Central

8 September 2017

Zhimin He

6

1 reference

Europe PubMed Central

8 September 2017

publication date

6 October 2013

1 reference

Europe PubMed Central

8 September 2017

Molecular and Cellular Biochemistry

1 reference

Europe PubMed Central

8 September 2017

386

1 reference

Europe PubMed Central

8 September 2017

63-71

1 reference

Europe PubMed Central

8 September 2017

1-2

1 reference

Europe PubMed Central

8 September 2017

https://scigraph.springernature.com/pub.10.1007/s11010-013-1845-x

0 references

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Metformin and cancer: new applications for an old drug

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Metformin inhibits melanoma development through autophagy and apoptosis mechanisms.

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Metformin interacts with AMPK through binding to γ subunit.

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

2,2'-diphenyl-3,3'-diindolylmethane: a potent compound induces apoptosis in breast cancer cells by inhibiting EGFR pathway

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Ultraviolet (UV) and hydrogen peroxide activate ceramide-ER stress-AMPK signaling axis to promote retinal pigment epithelium (RPE) cell apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Association between metformin therapy and mortality after breast cancer: a population-based study

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

The regulation of AMPK signaling in a natural state of profound metabolic rate depression

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

AMP-activated protein kinase (AMPK)/Ulk1-dependent autophagic pathway contributes to C6 ceramide-induced cytotoxic effects in cultured colorectal cancer HT-29 cells

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

AMP-activated protein kinase inhibits TGF-β-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11010-013-1845-X

21 January 2018

Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24096736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24096736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11010-013-1845-X

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39085692&oldid=1806956204"